MA31801B1 - Derives de 1,2,3-triazole destines a etre utilises comme inhibiteurs de la stearoyl-coa desaturase - Google Patents

Derives de 1,2,3-triazole destines a etre utilises comme inhibiteurs de la stearoyl-coa desaturase

Info

Publication number
MA31801B1
MA31801B1 MA32807A MA32807A MA31801B1 MA 31801 B1 MA31801 B1 MA 31801B1 MA 32807 A MA32807 A MA 32807A MA 32807 A MA32807 A MA 32807A MA 31801 B1 MA31801 B1 MA 31801B1
Authority
MA
Morocco
Prior art keywords
stearoyl
inhibitors
triazole derivatives
coa desaturase
relates
Prior art date
Application number
MA32807A
Other languages
Arabic (ar)
English (en)
Inventor
Anne Marie Jeanne Bouillot
Alain Laroze
Lionel Trottet
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA31801B1 publication Critical patent/MA31801B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

La présente invention porte sur des composés substitués du triazole représentés par la formule (i) et sur des sels pharmaceutiquement acceptables de ceux-ci, sur des compositions pharmaceutiques les contenant et sur leur utilisation en médecine. En particulier, l'invention porte sur des composés pour moduler l'activité de la scd.
MA32807A 2007-11-09 2010-04-30 Derives de 1,2,3-triazole destines a etre utilises comme inhibiteurs de la stearoyl-coa desaturase MA31801B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0722077.5A GB0722077D0 (en) 2007-11-09 2007-11-09 Compounds
PCT/EP2008/065104 WO2009060053A1 (fr) 2007-11-09 2008-11-07 Dérivés de 1,2,3-triazole destinés à être utilisés comme inhibiteurs de la stéaroyl-coa désaturase

Publications (1)

Publication Number Publication Date
MA31801B1 true MA31801B1 (fr) 2010-10-01

Family

ID=38858481

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32807A MA31801B1 (fr) 2007-11-09 2010-04-30 Derives de 1,2,3-triazole destines a etre utilises comme inhibiteurs de la stearoyl-coa desaturase

Country Status (32)

Country Link
US (2) US8486977B2 (fr)
EP (2) EP2368887B8 (fr)
JP (1) JP5491407B2 (fr)
KR (1) KR101577080B1 (fr)
CN (1) CN101918376B (fr)
AT (1) ATE512140T1 (fr)
AU (1) AU2008324172B2 (fr)
BR (1) BRPI0820471A2 (fr)
CA (1) CA2705113C (fr)
CO (1) CO6270331A2 (fr)
CR (1) CR11482A (fr)
CY (2) CY1112233T1 (fr)
DK (2) DK2207770T3 (fr)
DO (1) DOP2010000137A (fr)
EA (1) EA016621B1 (fr)
ES (2) ES2457521T3 (fr)
GB (1) GB0722077D0 (fr)
HK (2) HK1141528A1 (fr)
HR (2) HRP20110552T1 (fr)
IL (1) IL205152A (fr)
MA (1) MA31801B1 (fr)
ME (1) ME01962B (fr)
MX (1) MX2010005187A (fr)
MY (1) MY163126A (fr)
NZ (1) NZ584725A (fr)
PL (2) PL2207770T3 (fr)
PT (2) PT2207770E (fr)
RS (2) RS51918B (fr)
SI (2) SI2207770T1 (fr)
UA (1) UA107324C2 (fr)
WO (1) WO2009060053A1 (fr)
ZA (1) ZA201002596B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
CN102159605B (zh) * 2008-09-15 2014-01-08 大金工业株式会社 水性聚合物分散组合物和表面处理剂
KR20110082145A (ko) * 2008-10-21 2011-07-18 메타볼렉스, 인코포레이티드 아릴 ｇｐｒ１２０ 수용체 작동약 및 이의 용도
FR2974089B1 (fr) 2011-04-18 2014-04-25 Univ Nice Sophia Antipolis Derives de l'acadesine, produits et compositions les comprenant, leurs utilisations therapeutiques et leurs procedes de synthese.
WO2013134546A1 (fr) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Procédés et matériaux pour traiter le cancer
ES2605632T3 (es) * 2012-09-17 2017-03-15 F. Hoffmann-La Roche Ag Derivados triazol carboxamida
IL227890A0 (en) * 2013-08-08 2014-01-30 Galderm Therapeutics Ltd Antiaging compounds containing bile acid and fatty acid conjugates
CN107406420B (zh) 2015-01-30 2020-11-06 纽罗克里生物科学有限公司 取代的***及与其相关的方法
KR20180036318A (ko) * 2016-09-30 2018-04-09 경북대학교 산학협력단 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물
WO2018081167A1 (fr) 2016-10-24 2018-05-03 Yumanity Therapeutics Composés et utilisations de ces derniers
EA201991650A1 (ru) * 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
KR102292989B1 (ko) * 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
EP3700934A4 (fr) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. Composés et utilisations de ces composés
JP2021522253A (ja) 2018-04-25 2021-08-30 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
KR102017324B1 (ko) * 2018-04-30 2019-09-02 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도
CN114656414B (zh) * 2022-05-24 2022-08-23 常熟华虞环境科技有限公司 三氮唑改性二氧化钛光催化剂及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4460372A (en) 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4573996A (en) 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US20070087363A1 (en) 1998-12-22 2007-04-19 Myriad Genetics, Incorporated Therapeutic methods, compounds and compositions
AU2001247228B2 (en) 2000-02-24 2007-01-18 Wisconsin Alumni Research Foundation Stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents
EP1322767B1 (fr) 2000-09-26 2008-07-23 Xenon Pharmaceuticals Inc. Techniques et compositions utilisant une nouvelle stearyle-coa desaturase hscd5
PE20040600A1 (es) * 2002-04-26 2004-09-15 Lilly Co Eli Derivados de triazol como antagonistas del receptor de taquicinina
US20060160794A1 (en) * 2003-06-12 2006-07-20 Amegadzie Albert K Tachykinin receptor antagonists
BRPI0412343A (pt) 2003-07-30 2006-09-05 Xenon Pharmaceuticals Inc derivados de piridazina e seu uso como agentes terapêuticos
CN101693697A (zh) * 2003-07-30 2010-04-14 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
WO2007046868A2 (fr) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
WO2007046867A2 (fr) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Derives de piperidine et leurs utilisations comme agents therapeutiques
WO2008073461A2 (fr) 2006-12-11 2008-06-19 Wyeth Modulateurs de canaux ioniques
GB0625654D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625605D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625604D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
EP2125799A1 (fr) 2007-02-28 2009-12-02 Smithkline Beecham Corporation Dérivés de thiadiazole, inhibiteurs de stéoryl-coa désaturase
JP2010526850A (ja) * 2007-05-15 2010-08-05 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤として有用な、新規な芳香族複素環式カルボン酸アミド誘導体
GB0714129D0 (en) 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
GB0715055D0 (en) 2007-08-02 2007-09-12 Smithkline Beecham Corp Compounds
GB0721419D0 (en) 2007-10-31 2007-12-12 Smithkline Beecham Corp Compounds
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0810913D0 (en) 2008-06-13 2008-07-23 Smithkline Beecham Corp Comppounds

Also Published As

Publication number Publication date
ATE512140T1 (de) 2011-06-15
IL205152A (en) 2013-10-31
JP5491407B2 (ja) 2014-05-14
CA2705113C (fr) 2016-01-05
CA2705113A1 (fr) 2009-05-14
CY1115058T1 (el) 2016-12-14
RS51918B (en) 2012-02-29
IL205152A0 (en) 2010-11-30
HK1141528A1 (en) 2010-11-12
HRP20140346T1 (hr) 2014-05-09
RS53294B (en) 2014-08-29
HRP20110552T1 (hr) 2011-09-30
DK2207770T3 (da) 2011-09-12
MY163126A (en) 2017-08-15
AU2008324172A1 (en) 2009-05-14
ES2457521T3 (es) 2014-04-28
HK1160467A1 (en) 2012-08-17
MX2010005187A (es) 2010-05-27
US9051281B2 (en) 2015-06-09
AU2008324172B2 (en) 2012-03-15
ME01962B (fr) 2012-02-29
SI2207770T1 (sl) 2011-09-30
CR11482A (es) 2010-07-09
EA201070588A1 (ru) 2010-10-29
EP2368887B1 (fr) 2014-02-26
US20130281499A1 (en) 2013-10-24
DK2368887T3 (da) 2014-04-14
EP2368887A1 (fr) 2011-09-28
ES2366422T3 (es) 2011-10-20
BRPI0820471A2 (pt) 2015-06-16
PT2368887E (pt) 2014-05-15
EA016621B1 (ru) 2012-06-29
PL2207770T3 (pl) 2011-10-31
DOP2010000137A (es) 2010-08-15
US8486977B2 (en) 2013-07-16
SI2368887T1 (sl) 2014-05-30
ZA201002596B (en) 2010-12-29
UA107324C2 (uk) 2014-12-25
PL2368887T3 (pl) 2014-07-31
EP2368887B8 (fr) 2014-04-16
NZ584725A (en) 2012-05-25
JP2011503031A (ja) 2011-01-27
KR101577080B1 (ko) 2015-12-11
CY1112233T1 (el) 2015-12-09
GB0722077D0 (en) 2007-12-19
CN101918376A (zh) 2010-12-15
WO2009060053A1 (fr) 2009-05-14
KR20100095574A (ko) 2010-08-31
CO6270331A2 (es) 2011-04-20
CN101918376B (zh) 2013-11-06
US20100297054A1 (en) 2010-11-25
PT2207770E (pt) 2011-09-01
EP2207770B1 (fr) 2011-06-08
EP2207770A1 (fr) 2010-07-21

Similar Documents

Publication Publication Date Title
MA31801B1 (fr) Derives de 1,2,3-triazole destines a etre utilises comme inhibiteurs de la stearoyl-coa desaturase
WO2008074824A3 (fr) Composés
NZ600207A (en) Substituted 4-aminocyclohexane derivatives
EA200802329A1 (ru) Производные триазола ii
WO2008074834A3 (fr) Composés
MY143565A (en) Novel fluorocglycoside derivatives of pyrazoles: medicaments containing these compounds, and the use thereof
SI2150530T1 (sl) Substituirani sulfonamidni derivati
EA201000007A1 (ru) Производные индазоламида
WO2008074832A3 (fr) Composés
EA201100872A1 (ru) Производные хиназолинамида
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
WO2008074833A3 (fr) Composés
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
EA201200764A1 (ru) Производные хиназолина
MX2009007042A (es) S-nitrosotioles estables, procedimiento de sintesis y uso.